Zhounan Zhu

Zhounan Zhu

Auto-generated profile, based on publicly available information

Zhounan Zhu

Tongji University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2026 in Digital Health
Verified
Journal Article
Open access
RYRuoyi Yao
Ruoyi Yao
JYJiahao Ye
Jiahao Ye
ZZZhounan Zhu
Zhounan Zhu
CLChen Li
Chen Li
Purpose: This study aimed to evaluate the quality of dry eye disease (DED) treatment–related short videos on popular Chinese platforms. Methods: To better evaluate the quality of short videos related to DED treatment, the Dry-eye-related Short Videos Standardization Score (DSVSS), a preliminary disease-specific checklist, was developed tailored to DED clinical guidelines. On May 17, 2025, 305 videos (150 from Douyin, 155 from Bilibili) were retrieved using the keyword “dry eye treatment”, and their quality and guideline consistency were evaluated with the Global Quality Score (GQS) and the DSVSS checklist. Basic data, including duration, likes, comments, collections, and shares were recorded. Statistical analysis was performed using the Mann–Whitney U test, Kruskal–Wallis H test, and Spearman’s rank correlation to assess group differences and correlations. Results: Videos from Douyin were generally shorter but achieved higher user engagement, while videos from Bilibili were longer with lower interaction (both P <0.001). Median GQS was 3 for Douyin and 2 for Bilibili ( P =0.041), and median DSVSS was 3 for both ( P =0.116). Videos performed poorly in DSVSS checklist in definition and classification [0.05 (IQR 0.03–0.07)], emphasizing chronicity [0.07 (0.05–0.10)], and individualized treatment [0.08 (0.03–0.10)], but performed well in avoiding exaggeration [0.84 (0.63–0.91)], absence of advertising [0.78 (0.66–0.88)], and in providing warnings for special populations [0.91 (0.87–0.96)] (P<0.001). Conclusions: This study effectively identified critical deficiencies of current short-videos on DED treatment, underscoring the necessity for more professional, guideline-based content and stricter platform supervision to improve the quality of online health information.

1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
ZZZhounan Zhu
Zhounan Zhu
BZBin Zhang
Bin Zhang
WWWanyin Wang
Wanyin Wang
HYHongjie Yi
Hongjie Yi
CZChenggang Zheng
Chenggang Zheng
QTQinghe Tang
Qinghe Tang
Background: Hyperbaric oxygen treatment (HBOT) is clinically used to improve oxygen supply to hypoperfused tissues under certain conditions. HBOT can decrease the incidence of autoimmune diabetes in nonobese diabetic mice by reducing apoptosis and increasing β ‐cell proliferation. HBOT ameliorates glucose tolerance in Type 2 diabetes (T2D) mellitus patients, but the underlying mechanism needs further investigation. Methods: We used a diet‐induced T2D mouse model and a genetic mouse model (ob/ob mice) to evaluate the effects of HBOT on serum glucose levels in mice. The body weights and blood glucose levels of the mice were measured weekly. An oral glucose tolerance test (OGTT) was performed 12 weeks after the start of the experiment. All the mice were euthanized, and the serum and liver tissues were collected to test the total cholesterol, triglycerides, alanine aminotransferase, aspartate aminotransferase, malondialdehyde, and antioxidant enzymes. Results: Our results demonstrated that HBOT can delay/attenuate the onset of diet‐associated T2D in wild‐type mice. However, HBOT had no significant effects on blood glucose or T2D incidence in ob/ob mice. Furthermore, we found that HBOT improved glucose tolerance and liver steatosis in diet‐induced T2D model mice but not in ob/ob mice. Our results indicated that the effects of HBOT on T2D were dependent at least partly on the presence of leptin. Conclusion: Our study offers a rationale for using serum leptin as a predictor of clinical outcomes of HBOT and elucidates possible reasons why many patients may experience HBOT failure.